Original Article Biomol Ther 22(2), [removed])

First Page		Document Content
Gene delivery Cell biology Myeloid leukemia Acute leukemia Thymidine kinase Acute myeloid leukemia Bystander effect Ground Combat Vehicle Natural killer cell Biology Medicine Biotechnology		Original Article Biomol Ther 22(2), [removed]) Add to Reading List Source URL: www.ncbi.nlm.nih.gov Download Document from Source Website File Size: 738,26 KB Share Document on Facebook

	The Dual E-selectin/CXCR4 Antagonist GMI-1359 Exerts Anti-leukemia Efficacy Against FLT3-ITDmutated Acute Myeloid Leukemia in A Patient-derived Xenograft Murine Model Mouse-1 Mouse-2 DocID: 1uSbg - View Document
	A Phase I/II Study of GMI-1271, a Novel E-selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Previously Untreated Elderly Patients with Acute Myeloid Leukemia; Results to Date Dan DocID: 1uJQ2 - View Document
	Vascular E-Selectin Mediates Chemo-Resistance in Acute Myeloid Leukemia Initiating Cells Via Canonical Receptors PSGL-1 (CD162) and Hcell (CD44) and AKT Signaling Ingrid G Winkler, PhD1, Johanna M Erbani, PhD student2, DocID: 1u5Xi - View Document
	Regulatory Perspective: Acute Leukemia Clinical Endpoints Nancy S. Scher, MD, FACP DODP, CDER, FDA 1 DocID: 1tdCV - View Document
	· ACUTE LYMPHOBL ASTIC LEUKEMIA · Incorporating Antibodies into Treatment Strategies for Acute Lymphoblastic Leukemia Nicholas J. Short, MD, and Elias Jabbour, MD DocID: 1shAS - View Document